STAT+: An AI biotech CEO sets the record straight on AI drug development hype
SAN MATEO, Calif. β Peyton Greenside, CEO of BigHat Biosciences, has hot takes.Β
Her company designs antibody therapies using machine-learning, but she doesnβt like demos in which people open their computers and show off how fast they can design a drug. βIf you want me to design you a protein right now in six hours, Iβm happy to do it,β she said.
In fact, she can do it in 20 minutes. But if youβre actually in the business of making drugs, you are still going to have to do all the downstream tests, which take time and lots of money, Greenside said. βThatβs where the hard work is, is making the actual drug.βΒ
Continue to STAT+ to read the full storyβ¦


Β© THOM LEACH/SCIENCE PHOTO LIBRARY

